The failure of years of research to deliver efficacious AD therapy can be partially justified by the following consideration: various studies have illustrated the varied and complex pathophysiology beyond amyloid-β (Aβ) plaques and tau neurofibrillary tangles [1,2,3]. This evidence concerns the gene MAPT and Alzheimer disease.